{
  "docId": "019de075-5029-738c-8512-9456f77efe7c",
  "docSlug": "25c628cfc0779f52594519f9e322dc70",
  "documentTitle": "Genelux | Investor Presentation Deck | 38 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 38,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 24,
  "notes": "The slide uses a series of bar charts to compare PFS across multiple treatment regimens for three specific patients (15B-01, 15B-15, 15B-17).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-5029-738c-8512-9456f77efe7c/15",
  "deckHref": "/decks/019de075-5029-738c-8512-9456f77efe7c",
  "deckJsonHref": "/decks/019de075-5029-738c-8512-9456f77efe7c.json",
  "deckAnchorHref": "/decks/019de075-5029-738c-8512-9456f77efe7c#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.03,
        "y": 0.568
      },
      "kind": "chart",
      "text": "PFS comparison for patient 15B-01",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28fbc867-1b01-4236-8798-f6f34d95c993",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.36,
        "y": 0.568
      },
      "kind": "chart",
      "text": "PFS comparison for patient 15B-15",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63f883ea-99ed-40ba-9fa0-645b55cc3a7c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.69,
        "y": 0.568
      },
      "kind": "chart",
      "text": "PFS comparison for patient 15B-17",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f81e9e73-4f3e-489b-96c3-9de81e5c0adb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Patient profiles (15B-01, 15B-15, 15B-17) including stage, ECOG score, and biomarker status.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb661b6f-e36c-447d-b06d-0694b3043896",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.8,
        "x": 0.08,
        "y": 0.09
      },
      "kind": "title",
      "text": "Exemplary platinum-refractory patients, after platinum re-challenge, achieved PFS exceeding any prior lines",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a34cb940-fccc-408f-a883-2da3245b9752",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Olvi-Vec-Primed Immunochemotherapy Overcomes \"Refractoriness\"",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c51faa3b-0f32-47fb-a3b4-9de54c12bbe9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "f5209e33-dadd-4f53-bafb-17f37b2a93ca",
      "evidence": "list/bullet: Patient profiles (15B-01, 15B-15, 15B-17) including stage, ECOG score, and biomarker status.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 12,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "111fab6b-cd67-49dd-a414-d1390f2ab5d3",
      "evidence": "The presentation presents data on the clinical reversal of platinum resistance and refractoriness among patients with PRROC, highlighting the potential benefits of using Olvi-Vec.",
      "position": 0,
      "objective": "To highlight the cost of not using Olvi-Vec, specifically the limited treatment options for patients with platinum-resistant or platinum-refractory ovarian cancer",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}